Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 40

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Anti-neutrophil cytoplasmic antibody positive vasculitis

Recruiting

Study on Maintaining Remission in ANCA-Associated Vasculitis with Prednisone and Rituximab for Patients in Remission from Granulomatosis with Polyangiitis or Microscopic Polyangiitis

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Hospices Civils De Lyon

Endocrine ophthalmopathy

Recruiting

Study Comparing Sirolimus and Methylprednisolone for Patients with Active Thyroid Eye Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Methylprednisolone
  • Sponsor:Helse Bergen HF

Glomerulonephritis minimal lesion+3

Recruiting

Study on the Safety and Effects of Sparsentan for Children with Proteinuric Kidney Diseases

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Sparsentan
  • Sponsor:Travere Therapeutics Inc.

Myasthenia gravis

Recruiting

Study on Efgartigimod for Children Aged 2-17 with Generalized Myasthenia Gravis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Myasthenia gravis

Recruiting

Study on the Effects of Iptacopan in Patients with Generalized Myasthenia Gravis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Encephalitis autoimmune

Recruiting

Study on Bortezomib for Patients with Severe Autoimmune Encephalitis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Multiple sclerosis+1

Recruiting

Study on the Effects of Ozanimod in Patients with Relapsing-Remitting Multiple Sclerosis

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Ozanimod Hydrochloride
  • Sponsor:Ospedale San Raffaele S.r.l.

Crohn's disease

Recruiting

Study on the Effects of Zasocitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Crohn's disease

Recruiting

Study on Transmural Healing in Patients with Moderate to Severe Crohn's Disease Using Upadacitinib and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Alimentiv Inc.

Colitis ulcerative+2

Recruiting

Study on the Long-term Safety of Guselkumab for Children with Crohn's Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Indolent systemic mastocytosis

Recruiting

Study of TL-895 for Patients with Relapsed or Refractory Myelofibrosis or Indolent Systemic Mastocytosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:1-4-{[6-Amino-5-(4-Phenoxy-Phenyl)-Pyrimidin-4-Ylamino]-Methyl}-4-Fluoro-Piperidin-1-Yl)-Propenone
  • Sponsor:Telios Pharma Inc.

HIV infection

Recruiting

Study on HIV-1 Patients: Effects of Rilpivirine and Dolutegravir After Stopping Antiretroviral Therapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Dolutegravir
  • Sponsor:Ospedale San Raffaele S.r.l.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.